In the blood, contrary to the field of melanoma where several baseline immune predictors of response are described [e.g., baseline CD14+ CD16− HLA-DRhi monocytes (58) or baseline Ki67+ PD-1+ CD8+ T cells (59)], only one large study is available in NSCLC, including 466 patients treated with diverse PD-1/PDL-1 inhibitors. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.